[ad_1]
Moderna chief executive predicted that the existing vaccines would be less effective against Omicron than the previous Covid-19 complications and warned that it could take months for pharmaceutical companies to make various new jabs.
Stéphane Bancel said the increased Omicron mutations on spike protein, which the virus uses to transmit human cells, as well as the rapid spread of South Africa, say the current vaccine may need to be revised next year.
“There is no country, I think, where [the effectiveness] it is the same dose. . . we had Delta, “Bancel told the Financial Times in an interview at the company’s headquarters in Cambridge, Massachusetts.
He added: “I think that there will be a material collapse. I don’t know how many because we have to wait for the data. But all the scientists I spoke to. . . it’s like ‘this is not going to be good’. ”
The Moderna chief’s comments come as some health experts and politicians have tried to articulate the possibility of a vaccine available to protect them. Omicron.
On Monday, Scott Gottlieb, director of Pfizer and former U.S. Food and Drug Administration Commissioner, told CNBC: “There is a lot of confidence in the vaccine groups. [with] at least three doses. . . the patient will have the best protection against this condition. ”
Joe Biden, US President, later said Omicron was “scary, not scary, ”He added, and state health experts” believe that the vaccine will continue to provide protection against dangerous diseases. ”
However, Bancel said scientists are concerned because 32 of the 50 genes Omicron are based on a spike protein, which the current vaccine focuses on boosting the human immune system against Covid-19.
Many analysts think that such a radical change will not last for a year or two, Bancel added.
Bancel’s predictions have shocked investors in Asia, with equities and futures falling stocks and prices falling.
In Japan, the Nikkei 225 index dropped to 1.1 percent according to the FT report. Hong Kong’s Hang Seng index was down 2.3 percent. The future of the S&P 500 removed its initial gains for US stocks by about 1 percent, while the FTSE 100 had to shed 1.2 percent publicly in London.
Concerns about the diversion have prompted traders to seek security on bonds, which pushed the US Treasury yield 10 percent lower by 0.05 percent, while Brent crude, the global oil price index, fell to about 2 percent at $ 72.04 per year. mbiya.
Moderna and Pfizer have been the preferred vaccine providers in many developed countries for the success of their jabs, which are based on the expertise of messenger RNA (mRNA).
In August, Moderna announced that people who had received two jab vaccines “had stored antibodies for six months, in addition to antidepressants as a Delta species”.
But research shows that the company’s vaccine is less effective in preventing the spread of Delta than other strains of the virus.
Stanford University learning of a Delta explosion in a California prison that was published last month found that the company’s problem was 56.6 percent operating against disease. This was much lower than the amount of studies that took place before Delta was released, the researchers said.
Moderna and Pfizer are now working on a new vaccine to partner with the Omicron brand, which the World Health Organization calls a “high risk”.
Bancel said the evidence shows how the existing vaccine works against the Omicron brand, and if it causes serious infections, should be available within two weeks.
But he said it could take months for the Omicron vaccine to be developed in large quantities, and he said there could be a case of giving it to the elderly or people with a weakened immune system right now.
“[Moderna] and Pfizer will not be able to earn billions next week. Mathematics does not work. But can we produce billions by summer? Sure, “said Bancel, who predicted that Moderna could produce 2bn-3bn in 2022.
But he said it could be dangerous to transfer all of Moderna’s power into a jab controlled by Omicron while other species are still in operation.
Bancel also criticized critics who criticized the vaccine makers for not doing enough to support the spread of jabs in developing countries such as South Africa, which has a quarter of all people vaccinated, according to Johns Hopkins University.
“These were often the decisions of rich countries. In the US, we were told that we had no choice but to give 60 percent of our output to the US government. It was not the idea of Moderna, it was the idea of the US government,” he said.
Bancel also said that more jabs had been installed in Africa and that the Moderna 70m vaccine was in stock because Covax – an international organization that works to protect low-income countries – or one government had not taken it.
He said: “We need more space. This is because they have no customs clearance records, they do not have a refrigerator, or they have difficulty finding a standard for weapons. ”
[ad_2]
Source link
